Filing Flows

Filing Flows › Usana Health Sciences (USNA) › Stock forecast & fair value

Usana Health Sciences (USNA) stock forecast and fair value

Usana Health Sciences (USNA) trades at $14.95. One analyst's price target is $25.00 (+67%). Across 16 valuation methods the middle fair value is $45.65 (+205%).

Price$14.95
Median target$25.00
Fair value, middle$45.65
EPS beat rate40%
Usana Health Sciences fair value by method (price $14.95)Usana Health Sciences fair value by method (price $14.95)low – highpoint estimateEV/EBITDA vs peers$38.11EV/EBITDA vs peers, weighted$42.23EV/EBITDA vs peers, matched$45.65EV/Sales vs peers$223.27EV/Sales vs peers, weighted$305.47EV/Sales vs peers, matched$66.97Residual income$15.91Analysts' price targets$25.00Shareholder yield (dividends + buyb…$22.77Tangible book (asset value)$15.83

Fair value by method

MethodLowPointHighvs price
EV/EBITDA vs peers$26.10$38.11$60.59+155%
EV/EBITDA vs peers, weighted$38.09$42.23$42.81+182%
EV/EBITDA vs peers, matched$36.92$45.65$58.57+205%
EV/Sales vs peers$129.72$223.27$419.6315×
EV/Sales vs peers, weighted$198.66$305.47$436.0720×
EV/Sales vs peers, matched$60.18$66.97$126.16+348%
Residual income$15.33$15.91$16.52+6%
Analysts' price targets$25.00$25.00$25.00+67%
Shareholder yield (dividends + buybacks)$19.81$22.77$26.76+52%
Tangible book (asset value)$12.66$15.83$15.83+6%

Usana Health Sciences' latest quarter

Usana Health Sciences, Q2 2026: revenue $223M (-5% year over year), operating margin -9.0%, net loss $28.0M, operating cash flow $23.3M. The chart follows the revenue to costs, profit and cash.

Questions

What is the price target for USNA stock?

One analyst's 12-month target is $25.00, +67% from $14.95. The average rating is strong buy.

What is Usana Health Sciences' fair value?

The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $8.05 and $305.47, with a middle value of $45.65 against a price of $14.95. Each method's assumptions are on the page.

Does Usana Health Sciences usually beat earnings estimates?

It beat the consensus EPS estimate in 40% of the quarters on record.

Is USNA stock a buy?

Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.